198 results on '"Chand, Deepa H"'
Search Results
2. Review of cardiac safety in onasemnogene abeparvovec gene replacement therapy: translation from preclinical to clinical findings
3. Vascular Access and Peritoneal Dialysis Catheter Placement in Children
4. Neurofilament light chain and dorsal root ganglia injury after adeno-associated virus 9 gene therapy in nonhuman primates
5. Hemodialysis Vascular Access in Children
6. Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
7. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial
8. Drug-Induced Nephrotoxicity
9. Detection, Monitoring, and Mitigation of Drug-Induced Nephrotoxicity: A Pragmatic Approach
10. Pattern of Laboratory Parameters and Management of Secondary Hyperparathyroidism in Countries of Europe, Asia, the Middle East, and North America
11. Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
12. Chronic Kidney Disease: Treatment of Comorbidities II (Hypertension, Anemia, and Electrolyte Management)
13. Physician knowledge, attitudes, and practices regarding physical activity restrictions in pediatric hemodialysis patients
14. Hemodialysis Vascular Access
15. Causality Assessment and Examples of Adverse Drug Reactions (Drug-Induced Liver Injury, Renal, Skin, and Major Adverse Cardiac Events)
16. List of Contributors
17. 70 - Vascular Access and Peritoneal Dialysis Catheter Placement in Children
18. Hemodialysis Vascular Access in Children
19. Safety of Onasemnogene Abeparvovec for Patients With Spinal Muscular Atrophy 8.5 kg or Heavier in a Global Managed Access Program
20. Contributors
21. Vascular Access in Children
22. Mycophenolate mofetil-related leukopenia in children and young adults following kidney transplantation: Influence of genes and drugs
23. Gaining the Patient Reported Outcomes Measurement Information System (PROMIS) perspective in chronic kidney disease: a midwest pediatric nephrology consortium study
24. Correction to: Clinical Trial and Postmarketing Safety of Onasemnogene Abeparvovec Therapy
25. In vivo heat inactivation of serum can distinguish false positive cross matches in renal transplants
26. Barriers, biases, and beliefs about arteriovenous fistula placement in children: A survey of the International Pediatric Fistula First Initiative (IPFFI) within the Midwest Pediatric Nephrology Consortium (MWPNC)
27. The quality of cardiovascular disease care for adolescents with kidney disease: a Midwest Pediatric Nephrology Consortium study
28. Thrombotic Microangiopathy Following Onasemnogene Abeparvovec for Spinal Muscular Atrophy: A Case Series
29. Influenza vaccine after pediatric kidney transplant: a Midwest Pediatric Nephrology Consortium study
30. International Pediatric Fistula First Initiative: A Call to Action
31. Multicenter study of effects of pediatric peritoneal dialysis practices on bacterial peritonitis
32. Hemodialysis vascular access options in pediatrics: considerations for patients and practitioners
33. Central venous lines for chronic hemodialysis: survey of the Midwest Pediatric Nephrology Consortium
34. Blood pressure control in pediatric hemodialysis: the Midwest Pediatric Nephrology Consortium Study
35. Severe cardiac hypertrophy and long-term dialysis: the Midwest Pediatric Nephrolgy Consortium study
36. Contributors
37. Venous pressure monitoring does not accurately predict access failure in children
38. Hemodialysis Vascular Access in Children
39. Anatomy and Physiology of the Nephron
40. Neonatal Disorders
41. Immunosuppressive Medications for Transplantation
42. Hematuria
43. Clinician's Manual of Pediatric Nephrology
44. A comparison of laboratory values in pediatric hemodialysis patients: does day of the week matter?
45. Hemodialysis Vascular Access: Complications and Outcomes
46. Contributors
47. Capítulo 4 - Evaluación de la causalidad y ejemplos de reacciones adversas a medicamentos (lesión hepática inducida por fármacos, reacciones renales, reacciones cutáneas y eventos adversos cardiovasculares mayores)
48. Chapter 4 - Causality Assessment and Examples of Adverse Drug Reactions (Drug-Induced Liver Injury, Renal, Skin, and Major Adverse Cardiac Events)
49. A Vascular Access Team Can Increase AV Fistula Creation in Pediatric ESRD Patients: A Single Center Experience
50. Trial of metronidazole vs. azithromycin for treatment of cyclosporine-induced gingival overgrowth
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.